Moutai Invests in a Biotech Company

Recently, Comvikin has completed its Series B financing. The investors in this round include Puhua Capital, Delian Capital, CDH Investments, Orient Renaissance Capital, and the renowned Moutai. This round of financing will provide funding support for Comvikin to expand production capacity and optimize R&D, while also helping to accelerate the commercialization process of products to meet the growing market demand for high-quality biopharmaceuticals.

It is reported that Comvikin, which received this investment, was established in 2019 as a bio-synthesis technology platform company with an annual designed production capacity of 3,000 tons. The first phase of its Huizhou production base has already reached an annual output of 1,200 tons, making it a globally leading biocatalytic AP production line. Its product, ascorbyl palmitate, serves as a highly effective antioxidant and is widely used in food, health supplements, cosmetics, and pharmaceuticals. In addition, Comvikin continues to advance the research and development (R&D) and production of new products such as phytosterol esters and vitamin A palmitate, and has obtained multiple international certifications including ISO9001, US-FDA, HALAL, and KOSHER.

At the 2024 Annual Science and Technology Innovation Work Conference of Moutai Group, Chairman Ding Xiongjun clearly stated that the bioeconomy, with synthetic biology as its technological focus, should be regarded as an important direction for Moutai to develop emerging industries. He proposed that the group's future development should center on Moutai's innovation chains in material science, biological science, life science, and other fields, accelerate the development of emerging industries, and plan the layout of future industries.

As early as 2023, Kweichow Moutai(referring to Kweichow Moutai Co., Ltd.) collaborated with Goldstone Investment to establish a fund of 5.51 billion yuan Moutai&Goldstone Fund, on June 27 of the same year, together with other investors, established another specialized industry fund in Guizhou — Moutai Jinshi (Guizhou) Biotechnology Industry Fund Partnership (Limited Partnership) with a registered capital of 1.5 billion yuan. Moutai&Goldstone Fund, in collaboration with new investors, has established a 1.5-billion-yuan biotech industry fund. This marks the fund's second investment move to date, with both investments targeting the biotech sector.

Relying on funds, Mautai continues to invest in related enterprises in the field of biomanufacturing.

In early 2024, Synaura, a synthetic biology company, completed a multi-ten-million-yuan Series A financing round. The investors were Moutai Technology Innovation (Beijing) Investment Fund Partnership (Limited Partnership) and CICC Qide New Medicine (Guangzhou) Venture Capital Partnership (Limited Partnership) under CICC Capital.

On April 11, Mautai Fund announced its investment in Single-Cell Biotech for strategic investment. A new shareholder, Moutai Technology Innovation Fund, has been added, with a shareholding ratio of 2.2222%. Single-Cell Biotech is a high-tech enterprise focusing on the R&D of single-cell analysis instruments and supporting reagents and consumables.

This investment in Comvikin also marks another strategic move by Moutai in its layout of the synthetic biology sector.

Source: www.iivd.net